Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024:1447:139-149.
doi: 10.1007/978-3-031-54513-9_13.

Systemic Biologic Management of Atopic Dermatitis

Diem-Phuong D Dao  1 , R Hal Flowers  2
Affiliations
Review

Systemic Biologic Management of Atopic Dermatitis

Diem-Phuong D Dao et al. Adv Exp Med Biol. 2024.

Abstract

Dupilumab and tralokinumab are currently the only FDA-approved biologic therapies for the treatment of moderate-to-severe atopic dermatitis. Tralokinumab is approved for patients greater than 18 years old, and dupilumab is approved for patients as young as 6 months old. Both medications are effective in clinical trials at improving atopic dermatitis. With a good safety profile and low-risk adverse events, dupilumab and tralokinumab are generally excellent treatment options for patients with severe or refractory atopic dermatitis.

Keywords: Adverse effects; Atopic dermatitis; Biologics; Clinic trial; Dupilumab; IL-4 receptor inhibition; Immunomodulators; Pharmacokinetics; Tralokinumab; Biologic agents.

PubMed Disclaimer

References

    1. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10–22.e2. https://doi.org/10.1016/j.anai.2017.10.039 . PMID: 29273118. - DOI - PubMed
    1. Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection. J Allergy Clin Immunol Pract. 2020;8(1):91–101. https://doi.org/10.1016/j.jaip.2019.06.044 . Epub 2019 Aug 29. PMID: 31474543; PMCID: PMC7395647. - DOI - PubMed
    1. Freitas E, Guttman-Yassky E, Torres T. Tralokinumab for the treatment of atopic dermatitis. Am J Clin Dermatol. 2021;22(5):625–38. https://doi.org/10.1007/s40257-021-00613-8 . Epub 2021 Jun 21. PMID: 34155602. - DOI - PubMed
    1. Koskeridis F, Evangelou E, Ntzani EE, Kostikas K, Tsabouri S. Treatment with Dupilumab in patients with atopic dermatitis: systematic review and meta-analysis. J Cutan Med Surg. 2022;26(6):613–21. https://doi.org/10.1177/12034754221130969 . Epub 2022 Oct 9. PMID: 36214355. - DOI
    1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s042lbl.pdf .

MeSH terms

LinkOut - more resources